ENTRY       D10411                      Drug
NAME        Tovetumab (USAN/INN)
FORMULA     C6400H9906N1726O2002S54
EXACT_MASS  144701.1314
MOL_WEIGHT  144791.0066
SEQUENCE    (Heavy chain)
            QVQLVESGGG LVKPGGSLRL SCAASGFTFS DYYMNWIRQA PGKGLEWVSY ISSSGSIIYY
            ADSVKGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCAREG RIAARGMDVW GQGTTVTVSS
            ASTKGPSVFP LAPCSRSTSE STAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS
            GLYSLSSVVT VPSSNFGTQT YTCNVDHKPS NTKVDKTVER KCCVECPPCP APPVAGPSVF
            LFPPKPKDTL MISRTPEVTC VVVDVSHEDP EVQFNWYVDG VEVHNAKTKP REEQFNSTFR
            VVSVLTVVHQ DWLNGKEYKC KVSNKGLPAP IEKTISKTKG QPREPOVYTL PPSREEMTKN
            QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPMLDSD GSFFLYSKLT VDKSRWQQGN
            VFSCSVMHEA LHNHYTQKSL SLSPGK
            (Light chain)
            DIQMTQSPSS LSASVGDRVS ITCRPSQSFS RYINWYQQKP GKAPKLLIHA ASSLVGGVPS
            RFSGSGSGTD FTLTISSLQP EDFATYYCQQ TYSNPPITFG QGTRLEMKRT VAAPSVFIFP
            PSDEQLKSGT ASVVCLLNNF YPREAKVQWK VDNALQSGNS QESVTEQDSK DSTYSLSSTL
            TLSKADYEKH KVYACEVTHQ GLSSPVTKSF NRGEC
            (Disulfide bridge: H22-H96, H'22-H'96, L23-L88, L'23-L'88, H134-L215, H'134-L'215, L135-L195, L'135-L'195, H147-H203, H'147-H'203, H222-H'222, H223-H'223, H226-H'226, H229-H'229, H260-H320, H'260-H'320, H366-H424, H'366-H'424; Glycosylation site: Asn-H296, Asn-H'296)
  TYPE      Peptide
EFFICACY    Antineoplastic, Anti-platelet-derived growth factor receptor alpha antibody
  TYPE      Monoclonal antibody
TARGET      PDGFRA [HSA:5156] [KO:K04363]
BRITE       Target-based classification of drugs [BR:br08310]
             Protein kinases
              Receptor tyrosine kinases (RTK)
               PDGFR family
                PDGFRA
                 D10411  Tovetumab (USAN/INN)
DBLINKS     CAS: 1243266-04-7
            PubChem: 172232504
///
